Skip to content
Important: This site presents data from the FDA Adverse Event Reporting System (FAERS). A report does not mean the drug caused the event. Full disclaimer.

Does CAPECITABINE Cause Hyperammonaemic encephalopathy? 60 Reports in FDA Database

Boost Your Natural Energy & Metabolism

Mitolyn — 6 exotic plants to unlock your body's fat-burning power. 90-day guarantee.

Try Mitolyn Now

According to the FDA Adverse Event Reporting System (FAERS), 60 reports of Hyperammonaemic encephalopathy have been filed in association with CAPECITABINE (Capecitabine). This represents 0.1% of all adverse event reports for CAPECITABINE.

60
Reports of Hyperammonaemic encephalopathy with CAPECITABINE
0.1%
of all CAPECITABINE reports
1
Deaths
37
Hospitalizations

How Dangerous Is Hyperammonaemic encephalopathy From CAPECITABINE?

Of the 60 reports, 1 (1.7%) resulted in death, 37 (61.7%) required hospitalization, and 10 (16.7%) were considered life-threatening.

Is Hyperammonaemic encephalopathy Listed in the Official Label?

This adverse event is not currently listed in the official FDA drug label for CAPECITABINE. However, 60 reports have been filed with the FAERS database.

What Other Side Effects Does CAPECITABINE Cause?

Diarrhoea (9,277) Nausea (6,248) Palmar-plantar erythrodysaesthesia syndrome (5,294) Fatigue (5,018) Death (4,422) Vomiting (4,111) Disease progression (3,808) Off label use (3,193) Malignant neoplasm progression (2,425) Asthenia (2,352)

What Other Drugs Cause Hyperammonaemic encephalopathy?

VALPROIC ACID (455) FLUOROURACIL (156) VALPROATE (120) DIVALPROEX (119) OXALIPLATIN (107) TOPIRAMATE (101) RISPERIDONE (96) QUETIAPINE (91) LEVETIRACETAM (71) LEUCOVORIN (62)

Which CAPECITABINE Alternatives Have Lower Hyperammonaemic encephalopathy Risk?

CAPECITABINE vs CAPIVASERTIB CAPECITABINE vs CAPLACIZUMAB CAPECITABINE vs CAPLACIZUMAB-YHDP CAPECITABINE vs CAPMATINIB CAPECITABINE vs CAPREOMYCIN

Related Pages

CAPECITABINE Full Profile All Hyperammonaemic encephalopathy Reports All Drugs Causing Hyperammonaemic encephalopathy CAPECITABINE Demographics